Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 92%
filed 2026-08-25
Item 5.02
Michael Guina was appointed Chief Operating Officer effective August 24, 2026, a material executive leadership change. While Matthew Lesmeister's departure from the COO role is also disclosed, the principal action disclosed is Guina's appointment to a C-suite position, making exec_appointment the most salient classification. The filing emphasizes the appointment date and Guina's transition from Chief Commercial Officer, with no additional compensation triggered by the change.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-25
Item 3.02
Bain Capital Private Credit sold 389,036 unregistered Class I common shares to feeder vehicles for approximately $10.1 million, relying on Section 4(a)(2) and Regulation S exemptions from Securities Act registration.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-25
Item 7.01
The Fund declared a regular distribution of $0.1875 per Class I Share, payable to shareholders of record as of August 31, 2026, with payment on or about September 30, 2026, and reinvestment plan options available.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-08-25
Banco Santander issued $2 billion in aggregate principal amount of Senior Non Preferred Fixed-to-Fixed Rate Notes in two tranches (5.005% due 2030 and 5.624% due 2034). The 6-K furnishes the underwriting agreement, supplemental indenture, and note forms for incorporation into the F-3 registration statement, evidencing creation of new direct financial obligations totaling $2 billion.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-25
Item 2.02
Box issued a press release on August 25, 2026 announcing financial results for the second fiscal quarter ended July 31, 2026, disclosing record revenue of $321.1 million (up 9%), GAAP operating margin of 10.2%, non-GAAP operating margin of 29.4%, and GAAP and non-GAAP diluted EPS of $0.09 and $0.40 respectively. The Item 2.02 disclosure explicitly states this is the announcement of quarterly financial results with the full press release attached as Exhibit 99.1, which is the standard format for earnings releases.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-25
Item 3.02
North Haven Private Income Fund A LLC completed an unregistered sale of approximately 21,465 Class I units for $0.4 million, relying on Section 4(a)(2) and Regulation D exemptions with accredited investor representations.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-08-25
Item 7.01
North Haven Private Income Fund A LLC declared a distribution of $0.1403 per unit payable on or around September 3, 2026, representing a capital return to unitholders.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-25
Item 5.02
Craig L. Tendler, M.D., was appointed as a director of Parabilis Medicines on August 22, 2026, to fill a newly created vacancy on the Board. Dr. Tendler brings over 30 years of oncology drug development experience, including two decades in senior leadership roles at Johnson & Johnson overseeing clinical development and medical affairs.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-25
Item 8.01
The filing discloses the declaration of regular distributions to stockholders of Class I and Class S common shares, with specific per-share amounts ($0.16500 for Class I, $0.14635 net for Class S), a record date of August 31, 2026, and a payment date of approximately September 30, 2026. This is a routine but material dividend distribution disclosure typical of closed-end funds and BDCs, affecting investor returns and capital allocation decisions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-25
Item 8.01
The filing discloses a material acquisition activity: Cyclerion's planned merger with Korsana Biosciences, Inc., with the board fixing the record date (September 4, 2026) for distribution of contingent value rights (CVRs) to shareholders in connection with the merger. This is a change-of-control transaction that would materially affect the registrant and its shareholders, making it a core M&A disclosure despite being filed under Item 8.01 rather than Item 1.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-25
Item 3.02
LGAM Private Credit LLC sold approximately 177,957 Common Units for $3.5 million at $19.53 per unit pursuant to subscription agreements, relying on Regulation S and other exemptions from Securities Act registration.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-08-25
Item 7.01
The company declared a regular distribution to unitholders of $0.1383 per unit, payable September 3, 2026.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-25
Item 2.03
Apollo Infrastructure Co LLC increased its revolving credit facility by $100 million under the Agreement dated January 12, 2026, bringing the aggregate principal amount to $500 million, creating a new direct financial obligation for the Borrowers (indirect subsidiaries).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-25
Item 3.02
Apollo Infrastructure Co LLC completed an unregistered private placement of approximately $40.6 million in equity securities across multiple share classes (Series I and Series II A-II, F-I, and I Shares) to accredited and non-U.S. investors under Section 4(a)(2), Regulation D, and Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-25
Item 3.02
B&R Technology Merger Corp. partially exercised its IPO over-allotment option, issuing 3,500,000 additional units at $10.00 per unit for $35,000,000 in gross proceeds, plus concurrent private placement units to the Sponsor. The issuance of Class A ordinary shares and warrants materially dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-08-25
Item 8.01
Range Capital issued an unsecured promissory note in the principal amount of up to $540,000 to its sponsor on June 18, 2026, with $180,000 outstanding as of August 21, 2026. This constitutes creation of a new direct financial obligation. Although the note is sponsor-related and tied to trust account contributions for a SPAC, it remains a material debt instrument with defined repayment terms and events of default, fitting the debt_issuance category.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 82%
filed 2026-08-25
Item 2.03
Blue Owl Credit Income Corp.'s subsidiary Core Income Funding VII entered into Amendment No. 2 to its senior secured revolving credit facility on August 20, 2026, amending eligibility criteria, concentration limits, and other terms. The amendment modifies key operational terms of the facility, constituting a material change to the registrant's direct financial obligations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-25
Item 3.02
PennantPark Private Income Fund issued 137,883 common shares for approximately $3.57 million in an unregistered private offering relying on Section 4(a)(2) and Regulation D exemptions, diluting existing shareholders' ownership.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-08-25
Item 5.07
Olin shareholders voted on August 25, 2026 to approve a transformative all-stock merger with Huntsman, with approximately 97% of votes cast in favor (81% of outstanding shares). The vote also included approval of the subsidiary merger and an advisory vote on named executive officer compensation related to the transaction.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-25
Item 5.02
Kwaku Temeng, a director and Chairman of the Nominating Committee, resigned effective October 1, 2026, due to disagreement with the Board regarding strategic direction and governance practices, specifically succession planning and research priorities. This is a clear director departure triggered by substantive governance disagreement, material to investors assessing board stability and strategic alignment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-25
Item 5.02
The filing discloses the election of Gregory Ciongoli as a Class II director effective immediately, with appointment to the Audit Committee and Nominating and Corporate Governance Committee. While the Item 5.02 also includes the resignation of two directors (Dr. Bennett and Dr. Karabelas), the principal disclosed action centers on the appointment of a new director with specific compensation details ($550,000 initial equity award, annual retainers, and committee assignments). The appointment of a director with substantial board experience and expertise is material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-08-25
Item 1.01
The Company's subsidiary FRE US exercised its option to acquire and assume a mining lease covering 1,662.8 acres in Georgia, paying $375,000 cash and 165,153 shares ($2,000,000 value) to acquire material mineral rights. This represents a material acquisition of operating assets and property rights central to the Company's rare earth business, disclosed under Item 1.01 as a material definitive agreement entry.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-25
Item 3.02
Apollo Asset Backed Credit Co LLC completed unregistered sales of equity securities totaling approximately $32.9 million across Series I and Series II share classes to third-party investors as of August 1, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-08-25
Item 8.01
Apollo Asset Backed Credit Co LLC declared distributions on multiple share classes with specified per-share amounts, payable on September 28, 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 80%
filed 2026-08-25
Item 5.02
Kohl's appointed Arianne Parisi as Senior Executive Vice President and Chief Customer Officer, a newly created role effective September 1, 2026, consolidating responsibility for omnichannel customer experience, marketing, brand, loyalty, and digital commerce under her leadership reporting to CEO Michael J. Bender. The filing also discloses the departure of Christie Raymond as Chief Marketing Officer, effective September 9, 2026.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-08-25
Item 7.01
The disclosure announces completion of two property dispositions (Fresenius Chicago and six-property Dollar General portfolio) that generated approximately $4.04 million applied to debt reduction and preferred equity redemption. While this is a financial event involving asset sales and debt reduction, it does not fit the specific categories of ma_activity (no merger or change of control), debt_issuance (debt reduction, not issuance), or dividend_distribution. The core event is a strategic asset disposition and capital redeployment, making financial_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-25
Item 7.01
Generate Biomedicines disclosed that draft clinical trial posters for its lead candidate GB-0895 were inadvertently made publicly available via the ERS website prior to the embargo expiration. The company proactively furnished the final posters as Exhibit 99.1 to ensure accurate disclosure of ongoing Phase 1 and Phase 3 trial data for asthma and COPD indications. This is a material operational/disclosure event involving clinical trial data for a development-stage biotech company, though the company's precautionary measure mitigates the severity.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-25
Item 7.01
The filing discloses that Somnigroup has received all requisite regulatory approvals for the closing of its merger with Leggett & Platt, with closing anticipated as early as August 26, 2026. This represents the completion phase of a material acquisition transaction previously announced on April 13, 2026, whereby Merger Sub will merge into Leggett & Platt, with Leggett & Platt becoming a direct wholly owned subsidiary of Somnigroup. This is a transformative M&A event material to any reasonable investor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-25
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of the 2026 Annual Meeting of Stockholders held on August 24, 2026. The filing presents voting results for two proposals: (1) election of six director nominees, with detailed vote counts for each nominee (For, Withhold, Broker Non-Votes), and (2) ratification of CBIZ CPAs P.C. as independent auditor. The disclosure is material as it documents shareholder approval of board composition and auditor appointment, both of which are significant governance matters affecting investor confidence.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-25
Item 1.01
Bleichroeder Acquisition Corp. III (SPAC) entered into a definitive Business Combination Agreement with Ursa Major Technologies, Inc., dated August 24, 2026, resulting in Ursa Major becoming a publicly traded company with a pre-money valuation of approximately $1.6 billion and post-transaction valuation of approximately $2.3 billion, supported by at least $350 million in committed PIPE capital and expected to close in Q1 2027.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-25
Item 3.01
BEST SPAC I received a deficiency notification from Nasdaq on August 19, 2026, stating that the Company no longer meets the minimum Market Value of Listed Securities (MVLS) of $35,000,000 required under Nasdaq Listing Rule 5550(b)(2), and also fails to meet alternative requirements under Rules 5550(b)(1) and 5550(b)(3). The Company has been granted a 180-day compliance period until February 15, 2027, with explicit warning that failure to regain compliance will result in written delisting notification. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-08-25
Item 1.01
The filing references Item 1.01 (material agreements) and discloses amendments to an agreement with J.J. Astor dated August 17 and August 19, 2026, but the actual substance of Item 1.01 is not provided in the excerpt—only a reference to exhibits. Without the full text of the Third Amendment or details of what the agreement covers, the specific nature of the material event cannot be determined. The domain appears financial or operational, but the event type cannot be classified with confidence into a specific category.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-25
The filing discloses a clinical development milestone: the first patient dosed in the DReAMzz Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea. This represents material operational progress for a clinical-stage biopharmaceutical company, building on prior positive Phase 2 RePOSA results and FDA Fast Track designation. While not a specific named event type, this is clearly an operational/clinical milestone that would affect a reasonable investor's assessment of the company's drug development progress and timeline.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-25
EX-99.1
This exhibit is a press release announcing GreenTree Hospitality Group's second quarter 2026 financial results, including total revenues (RMB235.1 million, down 18.7% YoY), net income (RMB21.3 million, down 86.6% YoY), and operational metrics for hotels and restaurants. The document explicitly states "GreenTree Hospitality Group Ltd. Reports Second Quarter of 2026 Financial Results" and presents detailed quarterly financial performance data, making it a classic earnings release disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-25
Item 7.01
The disclosure announces a technical collaboration between Electra (the SPAC target) and MinTech to integrate battery diagnostic equipment with AI-powered analytics for battery energy storage systems. This is a material operational/strategic partnership that advances Electra's core business capabilities and market positioning. While disclosed under Item 7.01 (Regulation FD Disclosure) rather than a dedicated M&A item, the collaboration represents a significant commercial relationship that would affect investor assessment of Electra's technology roadmap and competitive positioning ahead of the pending business combination.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-25
EX-99.1
This press release announces a $38.8 million commercial purchase order from Japanese client WOODMAN Inc. for NVIDIA B300 GPU-based server clusters, representing SuperX's first commercial collaboration with this customer and a significant expansion into Japan's AI infrastructure market. While the order is material in scale and strategic importance, it is fundamentally a large commercial contract/customer win rather than a discrete event fitting the specific taxonomy categories (not M&A, not a financial obligation like debt issuance, not a restructuring). This is best classified as an operational/strategic business event—a material contract and market expansion milestone.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-08-25
Item 8.01
The Board authorized a stock repurchase program of up to $12 million of Class B common stock, effective August 21, 2026, representing a significant capital return to shareholders.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-08-25
EX-99.1
This exhibit is a Secured Promissory Note dated August 18, 2026, for a principal amount of $3,000,000 issued by Second Spring Water, Inc. to Air Water Ventures Holdings Limited. The note is part of a $4.5 million series of Bridge Notes issued in contemplation of the Air Water Acquisition. This constitutes creation of a new direct financial obligation and is material to investors assessing the registrant's capital structure and financing arrangements.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-25
EX-99.1
TNL Mediagene received a Nasdaq Hearings Panel decision on August 23, 2026, granting continued listing subject to strict conditions: compliance with the minimum bid price requirement by September 21, 2026, and the stockholders' equity requirement by October 30, 2026. The press release explicitly states "There can be no assurance that the Company will satisfy the conditions of the Panel's decision or otherwise regain compliance with the applicable listing requirements, and a failure to do so would result in the delisting of the Company's securities from Nasdaq." This is a material delisting-risk disclosure under Item 3.01 equivalent, as the company faces imminent delisting if it fails to meet two quantifiable compliance milestones within 66 days.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-08-25
The 6-K discloses the appointment of Mr. Chan Chee Leong as Independent Director and Chair of Compensation Committee, and Mr. Tan Kwang Leng as Chief Financial Officer, both effective August 24, 2026. While the filing also mentions Mr. Liu Wen Tao's resignation as Independent Director, the principal disclosed action is the two new appointments to material roles (director and CFO), making exec_appointment the primary classification. These are material changes to the company's leadership structure.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-25
The 6-K discloses results of an extraordinary general meeting held on August 25, 2026, where shareholders voted on three resolutions: (1) a 15-for-1 share consolidation affecting both Class A and Class B shares, (2) adoption of amended memorandum of association, and (3) adoption of amended articles of association. The vote tallies are provided for each resolution. A share consolidation is a material capital structure change that would affect a reasonable investor's assessment of share ownership and voting rights.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-08-25
Game Your Game entered into a Stockholders' Agreement on August 24, 2026, establishing Altus Sports Group, Inc. as a majority-owned subsidiary (70% GYG ownership, 30% founding team) with $200,000 initial funding. This constitutes a material acquisition/formation activity under Item 1.01, representing a significant strategic expansion into sports talent representation, athlete branding, and sports marketing—a new business line distinct from the company's core golf technology platform. The press release emphasizes this as a major strategic initiative to "expand into the commercial infrastructure of sports" and participate in "a much larger part of the sports-industry economy."
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-25
EX-99.1
This exhibit discloses the voting results from an Extraordinary General Meeting held on August 24, 2026, where shareholders voted on four resolutions: (1) a 100:1 share consolidation, (2) a massive increase in authorized share capital from US$100,000 to US$20,000,000,000, (3) adoption of amended memorandum and articles of association, and (4) adjournment authority. All resolutions passed with overwhelming majorities. The disclosure of shareholder vote results at a general meeting is the core definition of shareholder_vote_results, and the material nature of the approved proposals—particularly the 100:1 consolidation and the 200,000-fold increase in authorized capital—makes this material to investors.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-08-25
EX-99.1
Creative Global Technology Holdings Ltd held an extraordinary general meeting on September 9, 2026, at which shareholders voted on amendments to the company's memorandum and articles of association, including changes to written resolution procedures, dispute resolution jurisdiction, and authorized share capital, as well as authorization for directors to implement the approved amendments.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-25
Item 8.01
OSR Health disclosed a Staff Determination Letter from Nasdaq notifying the company of its determination to delist the company's common stock and warrants for non-compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company submitted a timely hearing request on August 25, 2026, which will stay formal delisting pending the Panel's decision, but trading suspension is scheduled for August 26, 2026. This is a clear delisting risk disclosure under Item 8.01, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-08-25
EX-99.1
This exhibit is the CCH Holdings Ltd 2026 Second Equity Incentive Plan, a comprehensive equity compensation plan document that establishes the framework for granting stock options, restricted stock, restricted stock units, and other equity awards to directors, officers, employees, and consultants. The plan's stated purpose is to "attract and retain key personnel" and allow participants to "acquire and maintain an equity interest in the Company." This is a material disclosure of compensatory arrangements for executives and other eligible persons, falling squarely within the exec_compensation category.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-08-25
The 6-K discloses that Masonglory has regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)) after receiving a non-compliance notice on March 13, 2026. While the current filing announces resolution of the delisting risk through a share consolidation that restored the stock price above $1.00, the underlying event—the company's prior failure to maintain minimum listing standards and the associated delisting threat—is material to investors' assessment of the registrant's listing status and financial condition.
View raw filing on EDGAR →
8-K
Terminal Other
confidence 90%
filed 2026-08-25
Item 2.01
The Board unanimously approved a deleveraging plan and committed to the Company's likely full liquidation and dissolution. The Company completed the sale of 75.8% of its investment portfolio (~$73 million in gross proceeds), with approximately $65 million to be used to pay off the credit facility in full, and plans to seek shareholder approval for full liquidation and wind-down by year-end.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-08-25
EX-99.1
This exhibit discloses regulatory correspondence and Holcim's response regarding the acquisition of 99.99% of Inversiones ASPI S.A. (which holds 50.01% of CPAC) by Holcim Ltd. The filing clarifies the purchase price mechanics—an Enterprise Value of USD 1.5 billion adjusted to an Equity Value of S/ 3.7 billion (S/ 1,850,370,000 for the 50.01% stake), with final deductions of S/ 210,042,776 for debt payoff and excess transaction expenses, resulting in a Final Purchase Price of S/ 1,640,327,224. This is a material acquisition/change of control event that would significantly affect investor assessment of the registrant's ownership and valuation.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 96%
filed 2026-08-25
Item 3.01
Maison Solutions received a notification letter from Nasdaq on August 20, 2026, stating that the Company failed to timely file its Form 10-K for fiscal year ended April 30, 2026, and therefore no longer satisfies Nasdaq Listing Rule 5250(c)(1). The Company has 60 days to submit a compliance plan or face potential delisting.
View raw filing on EDGAR →